Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate [18F]-FMH3 by Positron Emission Tomography (PET) for Quantization of the Receptor Histamine-3 in Human

NCT01268020 is registered in ClinicalTrials.gov with Institute for Neurodegenerative Disorders as lead sponsor.

NCT NCT01268020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01268020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate [18F]-FMH3 by Positron Emission Tomography (PET) for Quantization of the Receptor Histamine-3 in Human
Lead sponsor
Institute for Neurodegenerative Disorders
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
October 31, 2012
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease